AccuStem Sciences, Inc.

ACUT

US00444A1016

Medical Equipment, Supplies & Distribution

Delayed OTC Markets Other stock markets 09:30:01 2024-05-23 EDT			5-day change	1st Jan Change
0.277 ^USD	-20.86%		0.00%	-55.73%

05-20	AccuStem Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-22	AccuStem Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Accustem Sciences Inc. announced that it expects to receive $2.67594 million in funding

April 04, 2022

Accustem Sciences Inc. announced a private placement of 1,337,970 common shares at the price of $2 per share for gross proceeds of $2,675,940 on April 5, 2022.

Latest news about AccuStem Sciences, Inc.

AccuStem Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-20	CI
AccuStem Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-22	CI
AccuStem Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
AccuStem Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
AccuStem Sciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Accustem Sciences, Inc. and Emeritusdx Announce Joint Product Development Agreement and Strategic Partnership	23-07-17	CI
Accustem Sciences Inc. Announces Resignation of Jeff Fensterer as Chief Operating Officer, Effective as of June 16, 2023	23-06-09	CI
AccuStem Sciences, Inc. Announces Collaboration Agreement with University Hospitals	23-06-06	CI
Accustem Sciences Inc. Announces Strategic Clinical and Operational Partnership	23-05-31	CI
Accustem Sciences Inc. Appoints Sean McDonald to Its Board of Directors	22-11-16	CI
Accustem Sciences Inc. Appoints Wendy Blosser as Director to Serve on the Board	22-04-05	CI
Accustem Sciences Inc. announced that it expects to receive $2.67594 million in funding	22-04-04	CI
AccuStem to Build Corporate Headquarters in Phoenix, Arizona	22-03-04	CI
AccuStem Sciences, Inc. Appoints New Executive Leadership Team	22-03-04	CI
AccuStem Sciences, Inc. Appoints Wendy Blosser as Chief Executive Officer	22-03-04	CI

AccuStem Sciences, Inc. is a clinical-stage diagnostics company. The Company is focused on developing and commercializing a suite of genomic tests that support decision-making along the entire continuum of oncology care. The Company's product candidate is StemPrintER, a 20-gene prognostic assay intended to predict the risk of distant recurrence (DR) in luminal (ER+/HER2-negative) breast cancer patients. In addition, the Company is focused on offering ancillary commodity testing (hereditary genetic testing, somatic mutation testing) that augments its assays and provides additional information to patients and physicians throughout the patient care continuum. The Company also holds licensing rights for the MicroRNA Signature Classifier (MSC) test, which is designed to help determine whether lung nodules identified by low-dose computed tomography (LDCT) screening are benign or malignant. The Company's wholly owned subsidiary is StemPrintER Sciences Limited.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Income Statement Evolution

More financial data

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ACCUSTEM SCIENCES, INC.	-55.73%	3.14M
ABBOTT LABORATORIES	-5.40%	181B
MEDTRONIC PLC	-0.80%	108B
BECTON, DICKINSON AND COMPANY	-6.15%	66.57B
DEXCOM, INC.	+2.49%	49.95B
CENCORA, INC.	+6.43%	43.84B
HOYA CORPORATION	+4.91%	41.71B
METTLER-TOLEDO INTERNATIONAL, INC.	+21.49%	31.59B
TERUMO CORPORATION	+14.45%	25.3B
WEST PHARMACEUTICAL SERVICES, INC.	-5.87%	23.94B